סנדוסטטין 30 מג LAR ישראל - עברית - Ministry of Health

סנדוסטטין 30 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  20 מג LAR ישראל - עברית - Ministry of Health

סנדוסטטין 20 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  10 מג LAR ישראל - עברית - Ministry of Health

סנדוסטטין 10 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סביבו ישראל - עברית - Ministry of Health

סביבו

novartis pharma services ag - telbivudine 600 mg - film coated tablets - telbivudine - treatment of chronic hepatitis b in patients with evidence of viral replication and active liver inflammation in adults over 16 years of age.the following points should be considered when initiating therapy with sebivo:- for hbeag - positive patients, sebivo treatment should only be initiated in patients with baseline hbv dna < 9log 10 copies/ml and baseline alt>or= 2x uln.- for hbeag - negative patients, sebivo treatment should only be initiated in patients with baseline hbv dna < 7log 10 copies/ml.

ויזודיין ישראל - עברית - Ministry of Health

ויזודיין

novartis pharma services ag - verteporfin 15 mg/vial - solution for infusion - verteporfin - visudyne is indicated for the treatment of patients with predominantly classic or occult subfoveal choroidal neovascularization due to age related macular degeneration, or with subfoveal choroidal neovascularization caused by other macular diseases.

גליבק 100 מ"ג כמוסות ישראל - עברית - Ministry of Health

גליבק 100 מ"ג כמוסות

novartis pharma services ag - imatinib as mesylate 100 mg - capsules - imatinib - treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ - cml) in chronic phase, accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist).

טסיגנה 200 מג ישראל - עברית - Ministry of Health

טסיגנה 200 מג

novartis israel ltd - nilotinib as monohydrate - קפסולות - nilotinib as monohydrate 200 mg - nilotinib - nilotinib - treatment of philadelphia chromosome positive chronic myeloid leukaemia (ph+ cml) in chronic or accelerated phase in patients resistant to or experiencing significant toxicity during treatment with imatinib.treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

טסיגנה 150 מג ישראל - עברית - Ministry of Health

טסיגנה 150 מג

novartis israel ltd - nilotinib as hydrochloride monohydrate - קפסולות - nilotinib as hydrochloride monohydrate 150 mg - nilotinib - nilotinib - treatment of adult patients with newly diagnosed philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.

ג'קאבי 5 מג ישראל - עברית - Ministry of Health

ג'קאבי 5 מג

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 5 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

ג'קאבי 15 מג ישראל - עברית - Ministry of Health

ג'קאבי 15 מג

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 15 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.